BRIEF—Third Harmonic announces pricing of upsized IPO

Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, has announced the pricing of its upsized initial public offering of 10,900,000 shares of its common stock at a public offering price of $17 per share.

The US company is seeking to raise $185.3 million through the offering.

Shares are expected to begin trading on the Nasdaq Global Market on September 15, 2022 under the ticker symbol “THRD.”

The offering is expected to close on September 19, 2022, subject to the satisfaction of customary closing conditions.